In this episode, Daphne Koller, founder and CEO of insitro—as well as the co-founder of Coursera, a MacArthur Award winner, and a former professor in the department of computer science at Stanford University—chats with a16z Bio + Health founding partner Vijay Pande. 

Together, they talk about Daphne’s career journey, how Daphne thinks about the last few decades of progress in AI, and how insitro leverages artificial intelligence and machine learning to explore biology through new models of discovery.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today marks the reboot of our journal club series, so you can look forward to seeing these episodes as part of our regular feed. 

This episode is a scientific deep dive on recent research published by Ben Cravatt, Professor in the Department of Chemistry at the Scripps Research Institute and co-founder of a diverse suite of chemoproteomic companies such as Vividion and Belharra Therapeutics, and Gene Yeo, Professor of Cellular and Molecular Medicine at the University of California, San Diego and co-founder of Locana Bio, Eclipse Bio, and Trotana Therapeutics. 

Ben and Gene are joined by Vineeta Agarwala, general partner at a16z Bio + Health, and bio deal team member Bryan Faust. 

Together, they’ll discuss some unexpected mechanistic results of finding covalent binders to a class of proteins that we are just starting to understand — RNA binding proteins — and the subsequent translational implications that they described in a recent paper published by the Cravatt and Yeo labs in Nature Chemical Biology. The paper outlines a potentially new therapeutic approach that uses small molecules to fundamentally rewire transcriptional networks in cancer cells.

Additional reading:

• Remodeling oncogenic transcriptomes by small molecules targeting NONO

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, a16z Bio + Health general partner Julie Yoo chats with Bassett Healthcare Network president and CEO Tommy Ibrahim. Together, they talk about Tommy's journey from practicing physician to health system leader, the challenges facing rural healthcare today, and how Tommy thinks about partnering and integrating with digital health entrepreneurs as a hospital executive.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode from the archives, originally published in February 2021, Jennifer Doudna, who won the 2020 Nobel Prize for the co-discovery of CRISPR-Cas9 with Emmanuelle Charpentier, chats with Vijay Pande, general partner at a16z Bio + Health. Together, they discuss  the future of biology, whether discovery itself can be engineered and industrialized, and how biology can shape our future.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jorge Conde, general partner at a16z Bio + Health, talks with Josh Mandel-Brehm, founding CEO of CAMP4. Together, they talk about how CAMP4 focuses on regulatory RNA (and what that means), how Josh thinks about platform companies, and what he’s learned as the founding CEO of the company.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In today's episode, Sam Corcos, CEO and cofounder of Levels Health, chats with Vijay Pande, general partner at a16z Bio + Health, about how Sam cofounded Levels, how to decide who becomes CEO if you have multiple cofounders, Levels’ approach to company culture and meetings, and how Sam thinks about the complicated world of healthcare regulations.

Additional reading:

• Levels' public investor updates, as mentioned by Sam in the episode

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Kurt Adams, CEO of Optum Financial, chats with Daisy Wolf, investment partner for a16z Bio + Health, and Marc Andrusko, investment partner for a16z focused on fintech, about Optum Financial, how consumers might interact with fintech while seeking care or participating in healthy behaviors, and what a fintech-integrated version of the healthcare experience could look like.

Additional reading from us:

• Payvidors, Unbundled: Opportunities in Healthcare Fintech
• Healthtech x Fintech’s Biggest Prize: The Financial Operating System for Healthcare 

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Joe Lonsdale, founder and managing partner at 8VC, joins Vijay Pande, founding partner of a16z Bio + Health, and Olivia Webb, editorial lead. Together, we talk about what factors lead to innovation vs stagnation, monopoly power in healthcare, and policy ideas to incentivize change, growth, and dynamism.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, talk to Kate Ryder, founder and CEO of Maven; Amanda Rees, cofounder and CEO of Bold Health; and Bill Porter, VP and GM, International, of Butterfly Network, about their B2C2B go-to-market motion.

This episode was originally recorded in late 2021, but it's still really relevant to builders, especially those exploring the B2C2B go-to-market motion. We talked about B2C2B in-depth in the second chapter of our Digital Health Builders Founder's Playbooks, also available at: https://a16z.com/digital-health-builders/

And finally, our last chapter of the Founder's Playbooks is coming soon, so hit subscribe and stay tuned!

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Kevin Parker, cofounder and CEO of Cartography Biosciences, joins Jorge Conde, general partner at a16z Bio + Health, and Olivia Webb, editorial lead, to discuss immuno-oncology, current challenges in drug targeting, and the mechanisms Cartography and others are using to advance the field of immunotherapeutics. 

This episode dives deep into the science behind immuno-oncology — but you don't necessarily have to be a scientist to follow along. You'll never look at a smoothie the same way again.

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.